Treatment outcomes of high-dose-rate intracavitary brachytherapy for cervical cancer: a comparison of Ir-192 versus Co-60 sources.
- Author:
Thanatip TANTIVATANA
1
;
Kanisa RONGSRIYAM
Author Information
- Publication Type:Original Article
- Keywords: Uterine Cervical Neoplasms; Brachytherapy; Cobalt-60; Iridium-192; Outcomes
- MeSH: Brachytherapy*; Cohort Studies; Disease-Free Survival; Humans; Methods; Multivariate Analysis; Proportional Hazards Models; Radiation Oncology; Radiotherapy; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms*
- From:Journal of Gynecologic Oncology 2018;29(5):e86-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To determine and compare treatment outcomes between cobalt-60 (Co-60) and iridium-192 (Ir-192) high dose rate (HDR) brachytherapy in stage IB2–IIIB cervical cancer patients at Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindrahiraj University. METHODS: A retrospective cohort study of patients diagnosed with cervical cancer and treated with radiotherapy at the Department of Radiation Oncology, Faculty of Medicine Vajira Hospital between 2004 and 2014. Survival rate was analyzed by Kaplan-Meier method and were compared between groups with log-rank test. Multivariate analysis was performed using Cox proportional hazards model. RESULTS: A total of 480 patients with cervical cancer and treated with radiotherapy were included, 274 patients for Ir-192 group and 206 patients for Co-60 group. The 2- and 5-year disease-free survival rate in Ir-192 group were 80.4% and 73.1% and in Co-60 group were 82.5% and 74.7%, respectively (p = 0.365). Overall survival rates at 2 and 5 years were 89.4% and 77% of the Ir-192 group, and 91.6% and 81.9% in the Co-60 group, respectively (p = 0.238). The complications were primarily grade 1 or 2. Grade 3 and 4 complications were found in 13 of 274 and 7 of 206 in Ir-192 and Co-60 groups, respectively (p = 0.232). Grade and clinical stage of cancer significantly affected the survival outcome. CONCLUSION: Cervical cancer patients who were treated with HDR Co-60 brachytherapy were comparable in survival and toxicity outcomes of those with HDR Ir-192 brachytherapy. Co-60 source has lots of economic advantages over Ir-192 and hence suitable for low resource radiotherapy setting.
